Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant staphylococcus aureus pneumonia

Pharmacotherapy

Volumn 34, Issue 5, 2014, Pages 473-480

  Caffrey, Aisling R ^a,b   Morrill, Haley J ^a,b   Puzniak, Laura A ^c   Laplante, Kerry L ^a,b,d  

^a PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c PFIZER INC   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

comparative effectiveness; linezolid; methicillin resistant Staphylococcus aureus pneumonia; MRSA; vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INTUBATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; REINFECTION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; VETERAN; COMPARATIVE STUDY; DRUG EFFECTS; ELECTRONIC MEDICAL RECORD; FACTUAL DATABASE; GROWTH, DEVELOPMENT AND AGING; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PNEUMONIA, BACTERIAL;

ACETAMIDES; ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, BACTERIAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN; VETERANS;

EID: 84899099894     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1390     Document Type: Article

References (39)

1. Bodi M, Ardanuy C, Rello J,. Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Crit Care Med 2001; 29 (4 suppl): N82-6. (Pubitemid 32319756)
2. David MZ, Daum RS,. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 2010; 23: 616-87.
3. Rubinstein E, Kollef MH, Nathwani D,. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 (suppl 5): S378-85. (Pubitemid 351717325)
4. Levine DP,. Vancomycin: a history. Clin Infect Dis 2006; 42 (suppl 1): S5-12. (Pubitemid 41832060)
5. Moellering RC Jr, Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42 (suppl 1): S3-4. (Pubitemid 41832059)
6. Rhee KY, Gardiner DF, Charles M,. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin Infect Dis 2005; 40: 1705-6. (Pubitemid 40720831)
7. Steinkraus G, White R, Friedrich L,. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-2005. J Antimicrob Chemother 2007; 60: 788-94. (Pubitemid 47434257)
8. Jones RN,. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 (suppl 1): S13-24. (Pubitemid 41832061)
9. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996; 38: 865-9. (Pubitemid 26413723)
10. Moise PA, Schentag JJ,. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16 (suppl 1): S31-4. (Pubitemid 32007934)
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A,. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44. (Pubitemid 44631403)
12. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138: 1356-62.
13. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG,. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94. (Pubitemid 38375611)
14. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH,. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97. (Pubitemid 37433574)
15. Rubinstein E, Cammarata S, Oliphant T, Wunderink R,. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12. (Pubitemid 32173626)
16. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B,. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90. (Pubitemid 34553708)
17. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22: 677-86.
18. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007; 60: 1361-9. (Pubitemid 350168334)
19. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH,. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980-92. (Pubitemid 36459702)
20. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54: 621-9.
21. Powers JH, Lin D, Ross D,. FDA evaluation of antimicrobials: subgroup analysis. Chest 2005; 127: 2298-9; author reply 300-1.
22. Powers JH, Ross DB, Lin D, Soreth J,. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 2004; 126: 314-5; author reply 15-6.
23. Kalil AC, Puumala SE, Stoner J,. Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 2004; 125: 2370-1. (Pubitemid 38788219)
24. Bauer TT,. Nosocomial pneumonia: therapy is just not good enough. Chest 2003; 124: 1632-4. (Pubitemid 37433549)
25. Lahey T,. Questionable superiority of linezolid for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: watch where you step. Clin Infect Dis 2012; 55: 159-60.
26. Masuta K, Oba Y, Iwata K,. Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: controversy continues. Clin Infect Dis 2012; 55: 161.
27. Torres A,. Antibiotic treatment against methicillin-resistant Staphylococcus aureus hospital- and ventilator-acquired pneumonia: a step forward but the battle continues. Clin Infect Dis 2012; 54: 630-2.
28. Wolff M, Mourvillier B,. Linezolid for the treatment of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2012; 55: 160-1.
29. Caffrey AR, LaPlante KL,. Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002-2009. Infection 2012; 40: 291-7.
30. Caffrey AR, Quilliam BJ, LaPlante KL,. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54: 4394-400.
31. Hamilton LA, Wood GC, Magnotti LJ, et al. Treatment of methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia with high-dose vancomycin or linezolid. J Trauma Acute Care Surg 2012; 72: 1478-83.
32. Chan JD, Pham TN, Wong J, et al. Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis. J Intensive Care Med 2011; 26: 385-91.
33. Tsukada H, Sakai K, Cho H, et al. J Infect Chemother 2012; 18: 715-21.
34. Aston JL, Dortch MJ, Dossett LA, Creech CB, May AK,. Risk factors for treatment failure in patients receiving vancomycin for hospital-acquired methicillin-resistant Staphylococcus aureus pneumonia. Surg Infect 2010; 11: 21-8.
35. Willke RJ, Glick HA, Li JZ, Rittenhouse BE,. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Int J Technol Assess Health Care 2002; 18: 540-54.
36. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy 2001; 21: 263-74. (Pubitemid 32208840)
37. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52: 285-92.
38. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134: 1200-7.
39. Hripcsak G, Knirsch C, Zhou L, Wilcox A, Melton GB,. Using discordance to improve classification in narrative clinical databases: an application to community-acquired pneumonia. Comput Biol Med 2007; 37: 296-304. (Pubitemid 46048784)